Get Rid of Dad Bod and Man Boobs: UK Guide

Getting rid of the dad bod and man boobs is a goal many men share, but achieving it requires understanding what is actually driving the changes in your body. Excess body fat, hormonal shifts, age-related muscle loss, and in some cases true glandular breast tissue growth all play distinct roles. The right approach depends on which factors apply to you, and whether lifestyle changes alone are sufficient or whether medical support is appropriate. This article covers the causes, evidence-based treatments, NHS guidance, realistic timescales, and when to see a GP.

What actually causes a dad bod and man boobs in men?

A dad bod is caused by excess visceral and subcutaneous fat driven by calorie surplus and reduced activity, while man boobs may be pseudogynaecomastia (fatty tissue) or true gynaecomastia caused by a relative excess of oestrogen over testosterone.

A dad bod and man boobs in men are caused by a combination of excess body fat, hormonal changes, and age-related muscle loss, though the underlying mechanisms differ between the two. The soft belly associated with a dad bod typically reflects an accumulation of visceral and subcutaneous fat, driven by a sustained calorie surplus, reduced physical activity, and poor sleep. Elevated cortisol has been associated with abdominal fat storage in observational studies, though the relationship is complex and the evidence is associative rather than directly causal. As men age, testosterone levels naturally decline, which can further encourage fat storage and reduce the body's ability to maintain lean muscle mass.

Man boobs, medically referred to as gynaecomastia or pseudogynaecomastia, are not always the same thing. Pseudogynaecomastia (also called lipomastia) is simply excess fatty tissue in the chest area and is directly linked to overall body fat levels. True gynaecomastia, by contrast, involves actual glandular breast tissue growth and is driven by a hormonal imbalance, specifically a relative excess of oestrogen compared to testosterone. This can occur during puberty, with certain medicines, liver disease, or as a consequence of obesity itself, since fat tissue converts androgens into oestrogen via a process called aromatisation.

Medicines associated with gynaecomastia in UK clinical practice include spironolactone, finasteride, dutasteride, antiandrogens, some antipsychotics, anabolic steroids, and cimetidine (an H2 receptor antagonist).^[11][16] Men taking any of these should speak to their GP before stopping or changing their medicine.

Other contributing factors include:

• Alcohol consumption, which can suppress testosterone and increase oestrogen

• Sedentary lifestyle, which accelerates muscle loss and fat gain

• Chronic stress, which is associated with elevated cortisol and abdominal fat accumulation

• Dietary patterns high in ultra-processed foods and refined carbohydrates

Understanding which type of chest enlargement is present matters clinically, because the treatment approach differs significantly between pseudogynaecomastia and true gynaecomastia.

Can losing weight get rid of chest fat and a soft belly?

Weight loss through a calorie deficit effectively reduces chest fat and abdominal fat when the cause is pseudogynaecomastia, but true gynaecomastia involves glandular tissue that does not resolve with diet and exercise alone.

Losing weight through a sustained calorie deficit can significantly reduce chest fat and abdominal fat, though the outcome depends on whether the chest enlargement is pseudogynaecomastia or true gynaecomastia. Pseudogynaecomastia, which is composed entirely of fatty tissue, responds well to weight loss: as overall body fat decreases, chest fat typically reduces alongside it. Visceral fat, which surrounds the abdominal organs, tends to respond well to lifestyle change, though individual variation is considerable. A soft belly driven by subcutaneous and visceral fat also responds to calorie restriction and increased physical activity.

True gynaecomastia, however, involves glandular tissue rather than fat, and this does not disappear with weight loss alone. Men with true gynaecomastia may find that losing weight improves the overall appearance of the chest by reducing surrounding fat, but the firm, disc-like glandular tissue beneath the nipple tends to persist. In these cases, medical or surgical assessment may be appropriate.

For the dad bod more broadly, the evidence supports a combination of:

• Calorie-controlled eating, with a modest deficit to support gradual, sustainable fat loss. NHS guidance and NICE recommendations for structured weight management programmes typically reference a deficit in the region of 500 to 600 kcal per day, adjusted to the individual

• Resistance training, which preserves and builds muscle mass, improving body composition even when the scale changes slowly

• Cardiovascular exercise, which supports energy expenditure and cardiovascular health

• Adequate sleep and stress management, both of which influence cortisol and appetite-regulating hormones such as ghrelin and leptin

Spot reduction, the idea that exercising a specific area burns fat there preferentially, is not supported by evidence. Fat loss occurs systemically, and the chest and abdomen will reduce as part of overall progress rather than in isolation.

Which treatments and medications can help men lose stubborn fat?

UK-licensed options include tirzepatide (Mounjaro), semaglutide injection (Wegovy), oral semaglutide, liraglutide (Saxenda), orlistat, and orforglipron (Foundayo), all indicated for adults meeting specific BMI thresholds alongside lifestyle changes.

Several evidence-based treatments and medications are available in the UK to support fat loss in men who have not achieved sufficient results through lifestyle changes alone. UK-licensed weight management medicines are indicated for adults with a BMI of 30 kg/m2 or above, or 27 kg/m2 or above in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidaemia.^[13][3] These thresholds reflect the licensed indications in the UK SmPCs; NHS commissioning through ICBs may apply additional criteria.

Incretin-based medicines are currently the most clinically significant class of weight management medicines available in the UK:

• Semaglutide injection (Wegovy), authorised by the MHRA for chronic weight management, is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying. It is available in doses up to 2.4 mg weekly, with a higher 7.2 mg weekly strength also MHRA-authorised.

• Tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist, is MHRA-authorised both for type 2 diabetes and for chronic weight management. It is administered as a weekly injection using a multiple-dose KwikPen.

• Oral semaglutide (Wegovy 25 mg tablets), MHRA-approved in June 2026 for chronic weight management, offers a non-injectable option for eligible adults. The starting dose is 1.5 mg daily, titrated over time.

• Liraglutide (Saxenda) is a daily injectable GLP-1 receptor agonist also licensed for weight management in the UK.

• Orlistat, available both on prescription and over the counter (as Alli 60 mg), works by reducing dietary fat absorption and remains a licensed option for weight management in adults.^[14]

• Orforglipron (Foundayo) is an oral GLP-1 receptor agonist that has received MHRA authorisation for weight management and represents a further non-injectable option.^[8]

These medicines are not standalone solutions and are intended to complement dietary and behavioural changes. They are not appropriate for everyone, and a clinical assessment is required before prescribing. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a medicine such as Mounjaro may be one option a prescriber considers if it is clinically appropriate.

For true gynaecomastia, treatment may include addressing the underlying cause, stopping a causative medication under medical supervision, or, in persistent cases, surgical referral. Tamoxifen is sometimes used off-label in specialist settings but is not a standard NHS first-line treatment for gynaecomastia in adults.^[16][17]

What does the NHS say about gynaecomastia and excess body fat?

The NHS considers gynaecomastia usually benign and often self-resolving, while NICE recommends weight management medicines as adjuncts to lifestyle change; surgical treatment for gynaecomastia is not routinely NHS-funded.

The NHS recognises gynaecomastia as a common and usually benign condition, and advises that in many cases it resolves on its own, particularly when it occurs during puberty or is linked to a reversible cause such as medication or weight gain. NHS guidance distinguishes between physiological gynaecomastia, which does not require treatment, and cases where an underlying cause needs to be identified and managed.

For excess body fat more broadly, NHS guidance aligns with NICE recommendations, which support a structured approach to weight management that begins with lifestyle intervention. NICE technology appraisals have recommended semaglutide injection (Wegovy) and tirzepatide (Mounjaro) for use within NHS specialist weight management services, subject to specific eligibility criteria.^[13] However, NHS commissioning of these medicines is determined locally by Integrated Care Boards (ICBs), and access may vary by region. NHS availability does not follow automatically from a NICE technology appraisal.

Key NHS and NICE positions on this topic include:

• Gynaecomastia caused by obesity may improve with weight loss, but glandular tissue will not resolve through diet and exercise alone

• Referral to an endocrinologist or breast surgeon may be appropriate for persistent or painful gynaecomastia

• Weight management medicines are recommended as adjuncts to lifestyle change, not replacements for it

• Surgical treatment for gynaecomastia is not routinely funded on the NHS and is generally considered only where there is significant psychological distress or a clear clinical indication, in line with NHS England Evidence-Based Interventions guidance

Men concerned about chest changes or unexplained weight gain should speak to their GP as a first step, who can arrange appropriate investigations and referrals.

How long does it realistically take to see results?

With lifestyle changes, NHS guidance suggests 0.5 to 1 kg per week is a safe target, meaning visible abdominal and chest changes may take several months; clinical trials of tirzepatide and semaglutide show greater reductions over 68 to 72 weeks.

Realistic timescales for visible fat loss and body composition change vary considerably depending on the approach taken, individual metabolism, starting weight, and consistency of effort. With lifestyle changes alone, NHS guidance considers a rate of around 0.5 to 1 kg per week to be a safe and sustainable target, meaning meaningful changes to the abdomen and chest may take several months to become visually apparent.

For men using NICE-recommended weight management medications, clinical trial data show more substantial results over longer periods. The SURMOUNT-1 trial of tirzepatide (Mounjaro) demonstrated average body weight reductions of around 15 to 22 per cent over 72 weeks, depending on dose, in people with obesity.^[10] Semaglutide injection (Wegovy) at 2.4 mg weekly showed average weight reductions of approximately 15 per cent over 68 weeks in the STEP 1 trial. The STEP UP trial of semaglutide at 7.2 mg weekly has reported greater weight reductions than the 2.4 mg regimen, though this higher-dose data is more recent. These figures come from clinical trial populations and individual results will vary.

In practical terms, men can expect:

• Weeks 1 to 4: Initial changes in appetite, energy, and possibly early weight reduction, particularly water weight

• Months 2 to 3: Gradual reduction in waist circumference and early improvements in body composition with consistent effort

• Months 3 to 6: More visible changes to the abdomen; chest fat may begin to reduce as overall body fat falls

• Beyond 6 months: Continued progress with sustained lifestyle changes or medication, with body composition continuing to improve

Patience is important. Rapid weight loss is associated with greater muscle loss and is harder to maintain. Men with true gynaecomastia should be aware that glandular tissue will not reduce over time regardless of the approach, and a separate clinical conversation about that component is worthwhile.

When should you see a GP about man boobs or unexplained weight gain?

See a GP promptly if chest changes are firm, tender, rapidly growing, unilateral, or accompanied by nipple discharge or testicular symptoms, as these require assessment to exclude serious causes including male breast cancer.

Men should see their GP if chest enlargement is accompanied by pain, tenderness, nipple discharge, or a hard or irregular lump, as these features require prompt clinical assessment to exclude rarer but serious causes. While gynaecomastia is almost always benign, male breast cancer, though uncommon, does occur, and any unilateral, firm, or rapidly growing breast change warrants evaluation. Testicular symptoms such as a lump, swelling, or pain should also prompt a GP review, as testicular tumours can cause gynaecomastia through the production of human chorionic gonadotrophin (hCG). A GP can arrange blood tests to assess hormone levels (including testosterone, LH, FSH, oestradiol, prolactin, and hCG where indicated), liver and kidney function, and thyroid status, all of which can contribute to both gynaecomastia and unexplained weight gain.

Unexplained weight gain, particularly when it occurs without a clear change in diet or activity, also merits a GP review. Conditions such as hypothyroidism, Cushing's syndrome, and hypogonadism can all cause weight gain and changes in body composition, and these are identifiable through straightforward blood tests. Similarly, if a man is taking a medication known to cause weight gain or hormonal changes, a GP can review whether an alternative is appropriate.

Seek advice from your GP if you notice any of the following:

• Breast tissue that is firm, tender, or growing rapidly

• Nipple discharge of any kind

• A testicular lump, swelling, or pain

• Unexplained weight gain over several weeks without dietary change

• Symptoms of low testosterone, such as fatigue, low mood, reduced libido, or loss of muscle mass

• Weight that is not responding to sustained lifestyle changes and is affecting your health or quality of life

For urgent concerns, such as chest pain or breathing difficulties, contact NHS 111 for advice or attend A&E if the situation is life-threatening. For non-urgent questions about weight management options, a GP appointment is the appropriate starting point. Suspected side effects from any medication can be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity only.
2. Single-dose 7.2 mg semaglutide (Wegovy) pen approved to treat adult patients with obesity.
3. Wegovy – European Public Assessment Report.
4. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
5. Tirzepatide | Drugs | BNF – NICE.
6. Tirzepatide: a medicine to manage type 2 diabetes and obesity.
7. First GLP-1 tablet for weight loss approved in the UK.
8. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes.
9. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial).
10. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial).
11. Spironolactone | Drugs | BNF – NICE.
12. Overweight and obesity in adults.
13. A guide for prescribing medicines to manage overweight and obesity (TA1026).
14. Orlistat: a medicine to treat obesity.
15. Breast reduction (male).
16. Incidence, Management, and Prevention of Gynecomastia and Breast Pain in Patients with Prostate Cancer Undergoing Antiandrogen Therapy: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
17. Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer. Strahlenther Onkol. 2020.

Frequently Asked Questions